Scientific Program
Diseases, Treatment Considerations, Lymphoid Malignancies, Myeloid Malignancies, Biological Processes
Pacific Ballroom Salons 15-17
(Marriott Marquis San Diego Marina)
Description:
Cellular metabolism and its role in the pathogenesis of hematologic malignancies is an emerging area of research. Recent studies implicate various cellular mechanisms by which oncogenic activation of metabolic pathways contribute to lymphoid and myeloid malignancies as well as their respective tumor environment. In this session, the speakers will discuss the role of deregulated cellular metabolism that contributes to lymphoid and myeloid malignancies and how they may provide novel insights with therapeutic relevance. The metabolic control of T cell differentiation and their function in immunity will also be discussed. This session highlights the opportunities for gaining novel mechanistic insights of hematologic malignancies through global metabolomic studies that has potential to impact the field of T-cell immunology, immunotherapies and facilitate translation to clinical practice.
Chair:
Megan S. S Lim, MD, PhD, Memorial Sloan Kettering Cancer Center
Disclosures:
Lim: Thermo Fisher Scientific: Research Funding.
Cellular metabolism and its role in the pathogenesis of hematologic malignancies is an emerging area of research. Recent studies implicate various cellular mechanisms by which oncogenic activation of metabolic pathways contribute to lymphoid and myeloid malignancies as well as their respective tumor environment. In this session, the speakers will discuss the role of deregulated cellular metabolism that contributes to lymphoid and myeloid malignancies and how they may provide novel insights with therapeutic relevance. The metabolic control of T cell differentiation and their function in immunity will also be discussed. This session highlights the opportunities for gaining novel mechanistic insights of hematologic malignancies through global metabolomic studies that has potential to impact the field of T-cell immunology, immunotherapies and facilitate translation to clinical practice.
Jürgen Maximilian Ruland
Institute of Clinical Chemistry and Pathobiochemistry and TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, Munich, Germany
Paolo Gallipoli, MD/PhD
Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
Ananda Goldrath, PhD
Allen Institute, Seattle, WA
denotes an abstract that is clinically relevant.
denotes that this is a ticketed session.